BioSpace News Archive

Cortexyme Presents Data Linking P. gingivalis Infection to Cardiovascular Disease Severity and Alzheimer’s Disease, Along With Evidence That Treatment With Atuzaginstat (COR388) Improves Biomarkers Associated With Both Diseases -- Researchers presented new preclinical data on atuzaginstat and the potential impact on cardiovascular disease and AD-associated neurodegeneration in two poster presentations at AAIC 2020 -- Cortexyme also presented phase 1

TCR2 Therapeutics Inc. (Nasdaq: TCRR) (“TCR2” or the “Company”), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a public offering price of $15.50 per share.

ESSA Pharma Inc. announced the pricing of an underwritten public offering of 7,100,000 common shares at a public offering price of US$6.00 per share, before underwriting discounts, for an aggregate offering of approximately US$42.6 million.

Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management will present at the following upcoming virtual investor conferences

Two South Carolina-based companies are teaming up to address the national shortage of COVID-19 testing kits.

La Jolla Pharmaceutical Company (Nasdaq: LJPC) announced today that its Board of Directors has appointed Larry Edwards as President and Chief Executive Officer.

The U.S. Food and Drug Administration continued to take action in the ongoing response to the COVID-19 pandemic

Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announces that it intends to rely on blanket exemptions issued by provincial securities commissions due to the COVID-19 outbreak that permit the Company to extend the filing deadline of certain continuous disclosure documents for a period of up to 45 days. The Company intends to rely on the exemptive relief to extend the date of filing of its annual financial statements for the ye

Atomo has announced that it has signed a binding agreement with US-based diagnostics specialist Access Bio Inc. (KOSDAQ: 950130) (Access Bio) that will see Atomo supply its unique, integrated rapid diagnostic test (RDT) devices to Access Bio for use with its rapid test strip for detection of antibodies to COVID-19.

BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical development company, announced the pricing of an underwritten public offering of 4,000,000 shares of common stock at a public offering price of $50.00 per share.